Alector Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Alector wird ein jährliches Gewinn- und Umsatzwachstum von 5.7% bzw. 7.8% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 16.8% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich -1432.8% betragen.

Wichtige Informationen

5.7%

Wachstumsrate der Gewinne

16.83%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	22.4%
Wachstumsrate der Einnahmen	7.8%
Zukünftige Eigenkapitalrendite	-1,432.80%
Analystenabdeckung	Good
Zuletzt aktualisiert	24 Mar 2026

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Alector Stock Jumps On Upgrade, But AL101 Interim Data Will Be Key

Mar 11

There's No Escaping Alector, Inc.'s (NASDAQ:ALEC) Muted Revenues Despite A 32% Share Price Rise

Jan 22

Alector, Inc.'s (NASDAQ:ALEC) Shares Bounce 32% But Its Business Still Trails The Industry

Sep 16

This Just In: Analysts Are Boosting Their Alector, Inc. (NASDAQ:ALEC) Outlook for This Year

Aug 13

Alector, Inc.'s (NASDAQ:ALEC) Shares Bounce 29% But Its Business Still Trails The Industry

Jul 24

US$5.26 - That's What Analysts Think Alector, Inc. (NASDAQ:ALEC) Is Worth After These Results

May 11

Alector, Inc. (NASDAQ:ALEC) Stock Catapults 27% Though Its Price And Business Still Lag The Industry

May 05

ABC Platform And Latozinemab Trial Will Yield Mixed Prospects

Apr 03 Alector's ABC platform and late-stage trials, like those for latozinemab, could significantly boost revenue if successful, addressing unmet medical needs.

Alector, Inc. (NASDAQ:ALEC) Not Doing Enough For Some Investors As Its Shares Slump 26%

Mar 21

Alector: Q4 Of 2025 FTD-GRN Treatment Data Is Important Inflection Point

Mar 13

Earnings Update: Alector, Inc. (NASDAQ:ALEC) Just Reported And Analysts Are Trimming Their Forecasts

Mar 01

The Market Doesn't Like What It Sees From Alector, Inc.'s (NASDAQ:ALEC) Revenues Yet As Shares Tumble 53%

Dec 23

Need To Know: Analysts Just Made A Substantial Cut To Their Alector, Inc. (NASDAQ:ALEC) Estimates

Nov 28

Alector, Inc. (NASDAQ:ALEC) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

May 11

Analysts Are Updating Their Alector, Inc. (NASDAQ:ALEC) Estimates After Its Full-Year Results

Mar 01

Gewinn- und Umsatzwachstumsprognosen

NasdaqGS:ALEC - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2028	15	-136	-113	N/A	6
12/31/2027	13	-135	-143	N/A	7
12/31/2026	37	-108	-115	N/A	8
12/31/2025	21	-143	-184	-184	N/A
9/30/2025	69	-108	-198	-197	N/A
6/30/2025	81	-115	-216	-216	N/A
3/31/2025	88	-123	-230	-229	N/A
12/31/2024	101	-119	-231	-230	N/A
9/30/2024	62	-158	-222	-221	N/A
6/30/2024	55	-161	-218	-217	N/A
3/31/2024	96	-121	-199	-197	N/A
12/31/2023	97	-130	-187	-184	N/A
9/30/2023	96	-141	-190	-187	N/A
6/30/2023	102	-143	-194	-190	N/A
3/31/2023	126	-135	-208	-204	N/A
12/31/2022	134	-133	-24	-20	N/A
9/30/2022	133	-136	-25	-21	N/A
6/30/2022	301	36	471	473	N/A
3/31/2022	227	-29	483	486	N/A
12/31/2021	207	-36	295	299	N/A
9/30/2021	198	-33	297	300	N/A
6/30/2021	21	-212	-189	-186	N/A
3/31/2021	18	-202	-190	-187	N/A
12/31/2020	21	-190	-172	-167	N/A
9/30/2020	22	-169	-154	-148	N/A
6/30/2020	19	-148	-144	-136	N/A
3/31/2020	23	-127	-125	-108	N/A
12/31/2019	21	-105	-115	-99	N/A
9/30/2019	24	-92	N/A	-88	N/A
6/30/2019	28	-76	N/A	-82	N/A
3/31/2019	28	-62	N/A	-81	N/A
12/31/2018	28	-52	N/A	127	N/A
9/30/2018	22	-45	N/A	143	N/A
6/30/2018	15	-39	N/A	159	N/A
3/31/2018	8	-35	N/A	171	N/A
12/31/2017	4	-32	N/A	-18	N/A
12/31/2016	0	-15	N/A	-13	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: ALEC wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: ALEC wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: ALEC wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: ALECDie Einnahmen des Unternehmens (7.8% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (10.4% pro Jahr).

Hohe Wachstumseinnahmen: ALECDie Einnahmen des Unternehmens (7.8% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: ALEC wird voraussichtlich in 3 Jahren unrentabel sein.

Wachstumsunternehmen entdecken

Unternehmensanalyse und Finanzdaten Status

Daten	Zuletzt aktualisiert (UTC-Zeit)
Unternehmensanalyse	2026/03/26 23:57
Aktienkurs zum Tagesende	2026/03/26 00:00
Gewinne	2025/12/31
Jährliche Einnahmen	2025/12/31

Datenquellen

Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.

Paket	Daten	Zeitrahmen	Beispiel US-Quelle ^*
Finanzdaten des Unternehmens	10 Jahre	Gewinn- und Verlustrechnung Kapitalflussrechnung Bilanz	SEC-Formular 10-K SEC-Formular 10-Q
Konsensschätzungen der Analysten	+3 Jahre	Finanzielle Vorausschau Kursziele der Analysten	Analysten Research Berichte Blue Matrix
Marktpreise	30 Jahre	Aktienkurse Dividenden, Splits und Aktionen	ICE-Marktdaten SEC-Formular S-1
Eigentümerschaft	10 Jahre	Top-Aktionäre Insiderhandel	SEC-Formular 4 SEC-Formular 13D
Verwaltung	10 Jahre	Das Führungsteam Direktorium	SEC-Formular 10-K SEC-Formular DEF 14A
Wichtige Entwicklungen	10 Jahre	Ankündigungen des Unternehmens	SEC-Formular 8-K

* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.

Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.

Analysemodell und Schneeflocke

Details des Analysemodells, das zur Erstellung dieses Berichts verwendet wurde, finden Sie auf unserer Github-Seite; außerdem bieten wir Leitfäden zur Nutzung unserer Berichte sowie Tutorials auf Youtube an.

Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.

Metriken für Industrie und Sektor

Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.

Analysten-Quellen

Alector, Inc. wird von 13 Analysten beobachtet. 8 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.

Analyst	Einrichtung
Alec Stranahan	BofA Global Research
Thomas Shrader	BTIG
Pete Stavropoulos	Cantor Fitzgerald & Co.

Alector Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus EPS estimates fall by 12%, revenue upgraded

Price target increased by 40% to US$2.88

Consensus estimates of losses per share improve by 20%

Alector, Inc. Reaffirms Revenue Guidance for the Year 2025

Price target decreased by 19% to US$3.83

Price target increased by 20% to US$5.71

Recent updates

Consensus EPS estimates fall by 12%, revenue upgraded

Alector Stock Jumps On Upgrade, But AL101 Interim Data Will Be Key

Price target increased by 40% to US$2.88

Consensus estimates of losses per share improve by 20%

Co-Founder notifies of intention to sell stock

Full year 2025 earnings: EPS and revenues exceed analyst expectations

There's No Escaping Alector, Inc.'s (NASDAQ:ALEC) Muted Revenues Despite A 32% Share Price Rise

Insufficient new directors

Alector, Inc. Appoints Neil Berkley as Chief Financial Officer, Effective December 10, 2025

Alector, Inc. Reaffirms Revenue Guidance for the Year 2025

Alector Announces Latozinemab, Failed to Meet the Criteria for Safety and Efficacy in A Phase 3 Clinical Trial

Alector, Inc. Commits to a Plan to Reduce Workforce by Approximately 49%

Alector, Inc. to Host Virtual Research and Development Event Highlighting PGRN Franchise and Brain Carrier Programs

Alector, Inc.'s (NASDAQ:ALEC) Shares Bounce 32% But Its Business Still Trails The Industry

Co-Founder recently sold US$129k worth of stock

Price target decreased by 19% to US$3.83

Co-Founder notifies of intention to sell stock

This Just In: Analysts Are Boosting Their Alector, Inc. (NASDAQ:ALEC) Outlook for This Year

Second quarter 2025 earnings: EPS and revenues exceed analyst expectations

Price target increased by 20% to US$5.71

Alector, Inc. Updates Revenue Guidance for the Year Ending 2025

Alector, Inc. to Report Q2, 2025 Results on Aug 07, 2025

Alector, Inc.'s (NASDAQ:ALEC) Shares Bounce 29% But Its Business Still Trails The Industry

Insufficient new directors

Alector, Inc. Announces Chief Financial Officer Changes

Co-Founder recently sold US$70k worth of stock

Co-Founder notifies of intention to sell stock

Consensus revenue estimates decrease by 14%, EPS upgraded

US$5.26 - That's What Analysts Think Alector, Inc. (NASDAQ:ALEC) Is Worth After These Results

First quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behind

Alector, Inc. (NASDAQ:ALEC) Stock Catapults 27% Though Its Price And Business Still Lag The Industry

Alector, Inc., Annual General Meeting, Jun 11, 2025

New minor risk - Share price stability

Alector Announces Completion of Enrollment in the PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Individuals with Early Alzheimer’s Disease

New minor risk - Market cap size

ABC Platform And Latozinemab Trial Will Yield Mixed Prospects

Alector Provides Executive Leadership Update

Alector, Inc. (NASDAQ:ALEC) Not Doing Enough For Some Investors As Its Shares Slump 26%

Alector: Q4 Of 2025 FTD-GRN Treatment Data Is Important Inflection Point

Co-Founder recently sold US$59k worth of stock

Price target decreased by 7.9% to US$4.22

Consensus revenue estimates fall by 67%

Co-Founder notifies of intention to sell stock

Earnings Update: Alector, Inc. (NASDAQ:ALEC) Just Reported And Analysts Are Trimming Their Forecasts

Full year 2024 earnings: EPS and revenues exceed analyst expectations

Alector, Inc. Provides Revenue Guidance for the Year Ending 2025

Insufficient new directors

The Market Doesn't Like What It Sees From Alector, Inc.'s (NASDAQ:ALEC) Revenues Yet As Shares Tumble 53%

Price target decreased by 22% to US$6.33

Co-Founder recently sold US$131k worth of stock

Co-Founder notifies of intention to sell stock

Need To Know: Analysts Just Made A Substantial Cut To Their Alector, Inc. (NASDAQ:ALEC) Estimates

Alector: Bleak Prospects After Alzheimer's Failure

Price target decreased by 37% to US$10.28

Alector, Inc. Announces Results from AL002 INVOKE-2 Phase 2 Trial in Individuals with Early Alzheimer’S Disease and Provides Business Update

Alector, Inc. announced that it expects to receive $50 million in funding from Hercules Capital, Inc., and other investors

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Alector, Inc.'s (NASDAQ:ALEC) Business And Shares Still Trailing The Industry

We Think Alector (NASDAQ:ALEC) Needs To Drive Business Growth Carefully

New minor risk - Share price stability

Alector, Inc. Presents Baseline Characteristics for Pivotal INFRONT-3 Phase 3 Clinical Trial at the 14th International Conference on Frontotemporal Dementias (ISFTD 2024)

Co-Founder recently sold US$129k worth of stock

Co-Founder recently sold US$129k worth of stock

Board Member recently sold US$228k worth of stock

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Alector, Inc. to Report Q2, 2024 Results on Aug 07, 2024

Alector Presents Baseline Characteristics for INVOKE-2 Phase 2 Clinical Trial of AL002 at the Alzheimer's Association International Conference® 2024 (AAIC®)

Alector, Inc.'s (NASDAQ:ALEC) Price Is Right But Growth Is Lacking

Co-Founder recently sold US$121k worth of stock